Back to search

Article

KRAS withdrawal in Cholangiocarcinoma leads to immune infiltration and tumor regression

2025-06-17

Abstract excerpt

<h4>Background and Aims</h4> Cholangiocarcinoma (CCA) is a liver cancer with poor survival rates. Current treatments, including targeted therapies for specific mutations, are limited and benefit only a small subset of patients. KRAS mutations are found in 15-40% of CCA, representing a new potential treatment target. Whether KRAS inhibition leads to CCA tumor regression is unknown partly due to the lack of condit...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
961c23b5-bccf-5e4b-a2b2-acb024f472d4
DOI
10.1101/2025.06.11.659210
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
KRAS withdrawal in Cholangiocarcinoma leads to immune infiltration and tumor regressionDOI 10.1101/2025.06.11.659210
Select a neighboring publication to make it the new centre.